Susan J. Lucas

Array ( [id] => 15963717 [patent_doc_number] => 20200165610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => ANTISENSE OLIGONUCLEOTIDE CONTROLLING EXPRESSION AMOUNT OF TDP-43 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/630141 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16112255 [patent_doc_number] => 20200208150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) [patent_app_type] => utility [patent_app_number] => 16/621754 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756896 [patent_doc_number] => 10975436 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders [patent_app_type] => utility [patent_app_number] => 16/028206 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 47 [patent_no_of_words] => 19072 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 312 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774909 [patent_doc_number] => 20190000993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => TREATMENT OF DEVELOPMENTAL SYNDROMES [patent_app_type] => utility [patent_app_number] => 16/022154 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16022154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210697 [patent_doc_number] => 20190117733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) [patent_app_type] => utility [patent_app_number] => 16/015460 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14407533 [patent_doc_number] => 20190169610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/000179 [patent_app_country] => US [patent_app_date] => 2018-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16000179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17192094 [patent_doc_number] => 11160824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-02 [patent_title] => Application of LNCRNAS ENST00000607393 siRNA in preparing preparation for treating glaucoma [patent_app_type] => utility [patent_app_number] => 16/618400 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 6462 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963725 [patent_doc_number] => 20200165614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => Core Master Regulators Of Glioblastoma Stem Cells [patent_app_type] => utility [patent_app_number] => 16/613402 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650271 [patent_doc_number] => 20200087665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => SYSTEMS [patent_app_type] => utility [patent_app_number] => 16/610787 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310805 [patent_doc_number] => 20200289543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => COBITOLIMOD FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE [patent_app_type] => utility [patent_app_number] => 16/612314 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17525704 [patent_doc_number] => 11298370 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Prophylactic or therapeutic agent for inflammatory bowel disease [patent_app_type] => utility [patent_app_number] => 16/607681 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 11693 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20744224 [patent_doc_number] => 12644121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-02 [patent_title] => HIV-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents [patent_app_type] => utility [patent_app_number] => 16/605922 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 98 [patent_no_of_words] => 26264 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16605922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533535 [patent_doc_number] => 10876120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Methods and compositions for reducing immunosupression by tumor cells [patent_app_type] => utility [patent_app_number] => 15/944330 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 44 [patent_no_of_words] => 32622 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15944330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16786352 [patent_doc_number] => 10988767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-27 [patent_title] => Inhibition of oxidative stress in atrial fibrillation [patent_app_type] => utility [patent_app_number] => 15/943069 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 21358 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15451327 [patent_doc_number] => 20200038487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => PREVENTION AND TREATMENT OF NON-MELANOMA SKIN CANCER (NMSC) [patent_app_type] => utility [patent_app_number] => 16/499683 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163691 [patent_doc_number] => 10487327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor [patent_app_type] => utility [patent_app_number] => 15/918645 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 26837 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297491 [patent_doc_number] => 20180200282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS [patent_app_type] => utility [patent_app_number] => 15/914138 [patent_app_country] => US [patent_app_date] => 2018-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15914138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413769 [patent_doc_number] => 20180258427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => MODIFIED iRNA AGENTS [patent_app_type] => utility [patent_app_number] => 15/906908 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15906908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294943 [patent_doc_number] => 10287589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Targeting microRNAs for metabolic disorders [patent_app_type] => utility [patent_app_number] => 15/900169 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 34621 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15449223 [patent_doc_number] => 10548842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer [patent_app_type] => utility [patent_app_number] => 15/899682 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 45 [patent_no_of_words] => 5434 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15899682 [rel_patent_id] =>[rel_patent_doc_number] =>)